medigraphic.com

2016, Number 1

<< Back Next >>

Rev Clin Esc Med 2016; 6 (1)

Papilomatosis respiratoria: Nuevas terapias adyuvantes

Valverde ZA, Zamora M

Language: Spanish
References: 21
Page: 81-86
PDF size: 787.87 Kb.


ABSTRACT

Respiratory papillomatosis is a disease caused by the papilloma human virus. Although infrequent, it is the most common cause of benign larynx neoplasm in the pediatric population, and it is one of the first differential diagnoses of stridor and hoarseness in children. Although surgical therapy continues to be its main treatment, adjuvant therapy has been implemented during the last few decades with the purpose of reducing the number of surgical interventions and achieving remission of the disease. The main objective of this paper is to analyze such adjuvant therapy and its benefits.


REFERENCES

  1. Donne A, Clarke R. Recurrent respiratory papillomatosis: an uncommon but potentially devastating effect of human papillomavirus in children. International Journal of STD & AIDS. 2010; 21: 381–385

  2. Reeves W et al. National Registry for JuvenileOnset Recurren t Respiratory Papillomatosis. Arch Otolaryngol Head Neck Surg. 2003;129: 976-982

  3. Tasca R, McCormick M, Clarke R. Briish Association of Paediatric Otorhinolaryng ogy members experience with recurrent respirato ry papillomatosis. International Journal of Pediat ric Otorhinolaryngology 2006; 70:1183—1187

  4. Sidell D et al. HighDose Sublesional Bevacizumab (Avastin) for Pediatric Recurrent Respiratory Papillomato sis. Annals of Otology, Rhinology & Laryngolog y. 2014; 123(3): 214–221􀀀

  5. Chung B, Akst L, Koltai P. 3.5-Year follow-up of intralesional cidofovir protocol for pediatric recurrent respiratory papillomatosis. International Journal of Pediatric Otorhinolaryngology. 2006; 70: 1911—1917

  6. Omland T et al. Recurrent Respiratory Papillomatosis: HPV Genotypes and Risk of High- Grade Laryngeal Neoplasia. PLOS ONE. 2014; 9(6): 1-7.

  7. Hall J et al. Natural Progression of Dysplasia in Adult Recurrent Respiratory Papillomatosis. Otolaryngology–􀀀Head and Neck Surgery􀀀 2011; 144(2) : 252–256

  8. Carifi M et al. Recurrent respiratory papillomatosis: current and future perspectives. Therapeutics and Clinical Risk Management 2015; 11 : 731–738

  9. Correia S, Dionisio J, Duro da Costa J. Recurrent respiratory papillomatosis of the airway: The experience of an endoscopic unit. Rev Port Pneumol. 2015; 21(2):82-89

  10. Chadha N, James A. Adjuvant antiviral therapy for recurrent respiratory papillomatosisCochrane Database of Systematic Reviews 2010; 1: 1-14.

  11. Rojo P et al. Papilomatosis respiratoria recurrente: una c ausa de dificultad respiratoria progresiva. Anales Españoles De Pediatría. 2001; 55(6): 558-560.

  12. Fusconi M et al. Recurrent respiratory papillomatosis by HPV: review of the literature and update on the use of cidofovir. Acta Otorhinolaryngol Ital 2014; 34: 375-381

  13. Maturo S, Hartnick J. Use of 532- nm Pulsed Potassium Titanyl Phosphate Laser and Adjuvant Intralesional Bevacizumab for Agg ressive Respiratory Papillomatosis in Children.Arc h Otolaryngol Head Neck Surg. 2010; 136(6):561-565

  14. Cespedes M et al. Adult-Onset Recurrent Respiratory Papillomatosis: A Review of Disease Pathogenesis and Implications for Patient Counseling. JAMA Otolaryngol Head Neck Surg. 2015;141(1):78-83

  15. Palomar V et al. Actividad del cidofovir en la papilomatosis respiratoria infantil recidivante Acta Otorrinolaringol Esp 2005; 56: 22-24

  16. Ksiazek J et al. Inhaled Cidofovir as an Adjuvant Therapy for Recurrent Respiratory Papillomatosis. Otolaryngology–􀀀Head and Neck Surgery􀀀. 2011. 144(4) : 639–641􀀀

  17. Durvasula V, Richter G. Intralesional cidofovir as adjuvant for the successful management of aggressive respiratory papillomatosis in an infant. International Journal of Pediatric Otorhinolaryngology. 2013; 77: 1912–1915

  18. Rosen C, Bryson P. Indole-3-Carbinol for Recurrent Respiratory Papillomatosis: Long- Term Results. Journal of Voice. 2004; 18(2): 248–253

  19. Suter-Montano T et al. Adult Recurrent Respirator Papillomatosis: A New Therapeutic Approach with Pegylated Interf eron Alpha 2a (Peg-IFNa-2a) and GMCSF. Otolaryngology–􀀀Head and Neck Surgery􀀀. 2013; 148(2) 253–260􀀀

  20. Leventhal GB et al. Long-term response of recurrent respiratory papillomatosis to treatment with lymphoblastoid interferon alfanl. N Engl J Med 1991; 325:613-7.

  21. Avidano M, Singleton G. Adjuvant drug strategies in the treatment of recurrent respiratorypapillomatosis. Otolaryngol Hea d Neck Surg. 1995; 12:197-202ry papillomatosis. International Journal of Pediat ric Otorhinolaryngology 2006; 70:1183—1187




2020     |     www.medigraphic.com